Biotechnology, Pharmaceutical and Life Science Reports and Courses

Main Pages

    Best Selling Products

    BioNewsCast Press Release Distribution Service

    BioNewsCast Press Release Distribution Service

     

    3rd Annual Stability Testing Conference

    3rd Annual Stability Testing Conference

     

    Next-Gen Sequencing Trends 2009

    Next-Gen Sequencing Trends 2009

     

    Competitor Analysis: c-MET/HGF Inhibitors

    Competitor Analysis: c-MET/HGF Inhibitors

     

    The Japanese Pharmaceutical Market 2008-2023

    The Japanese Pharmaceutical Market 2008-2023

     

    New Products

    Japanese Pharmaceutical Market 2009-2024

    Japanese Pharmaceutical Market 2009-2024

     

    3rd Annual Lyophilisation Conference

    3rd Annual Lyophilisation Conference

     

    The Global Bioinformatics Market: Market size, forecasts and company profiles

    The Global Bioinformatics Market: Market size, forecasts and company profiles

     

    Pharmaceutical Mergers and Acquisitions (PH133)

    Pharmaceutical Mergers and Acquisitions (PH133)

     

    Pharmaceutical Speaker Programs (PH134) Measuring ROI and Communicating Value

    Pharmaceutical Speaker Programs (PH134) Measuring ROI and Communicating Value

     

    Strategic Clinical Sourcing (PH125)) Managing Costs and CROs

    Strategic Clinical Sourcing (PH125)) Managing Costs and CROs

     

    The Global Analgesics Market 2009-2024

    The Global Analgesics Market 2009-2024

     

    Competitor Analysis: Coagulation Factors

    Competitor Analysis: Coagulation Factors

     

    Competitor Analysis: PDGF-R Agonists and Antagonists

    Competitor Analysis: PDGF-R Agonists and Antagonists

     

    World Market for Addiction Disorders, 2009-2016

    World Market for Addiction Disorders, 2009-2016

     

    BioPortfolio | Insight Pharma Reports |  Stem Cells Come of Age Report Overview

    Stem Cells Come of Age Report Overview

    Stem Cells Come of Age Report Overview


    Author: Ricki Lewis, PhD

    Commercialization of stem cells can potentially help to treat an astounding variety of medical conditions. After a slow start, the stem cell age is finally poised to begin, as numerous factors converge to catapult stem cell technology into the medical mainstream. This report considers:

    * The current state of stem cell science and technology

    * Supplies and services

    * Major applications of stem cell science

    * Sources of funding, regulatory hurdles, and the commercial outlook

    * IP challenges, public perception, bioethical concerns, and diversity in policies

    Stem cell science is on the precipice of becoming big business. These enigmatic cells lie at the heart of a fledgling technology with great clinical promise. Stem Cells Come of Age analyzes the current state of stem cell science and technology, and explores some of the non-scientific issues that are part of the emerging, complex, stem cell picture. We begin by tracing the experiments that set the stage for today’s stem cell technology, as well as examining the state of “stemness” and factors outside the genome that affect cell fate. Human embryonic stem (ES) and induced pluripotent stem (iPS) cells are contrasted—while each can become any cell type of the body (i.e., are pluripotent), each has its own niche.

    Figure

    We consider the technological landscape, continuing our look at ES and iPS cells with a description of many types of multipotent, or “adult,” stem cells, which are more restricted in their fates, and how we might use them. We cover the care and feeding of stem cells—their isolation, derivation, culture, and characterization. We explore how stem cells fit into tissue engineering, and then consider suppliers of reagents, devices, and materials.

    Stem Cells Come of Age highlights three major applications of stem cell science. In drug discovery and development, stem cells are being used to identify novel drug targets, describe the earliest inklings of disease, and reveal disease subtypes. ES and iPS cells will be particularly valuable in the second major arena for stem cell science, recapitulating pathogenesis in vitro. In the third area, therapeutics, we take a closer look at three therapeutic goals: treating the failing heart, cancer, and eye diseases.

    We present a commercial outlook, looking at a mix of areas that are critical to the translation of stem cell science from bench to bedside. Pharma is just beginning to fund stem cell research at academic centers and biotech companies, and venture capitalists are on the lookout for researchers who can succinctly pitch a stem cell-based product or service.

    Expert roundtables and exclusive interviews offer the voices of those in the field of stem cell research. These conversations reveal how the people who invented the enabling technologies and have done groundbreaking experiments think and share ideas. Finally, we profile a handful of companies that work with stem cells or supply the tools of the trade, selected for their diversity.

    Length 200 pages Date published November 2008
    Table of Contents

    Price



    BioPortfolio uses RBS Worldpay Secure Server for credit card transactions